📰 Clinical Development News
Page 99 - Clinical Development News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Clinical Development. Real-time updates on events, politics, business and more.
July 21, 2023
/PRNewswire/ -- The "LATUDA Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.coms offering. "This "LATUDA Drug...
July 21, 2023
/PRNewswire/ -- The "CAPLYTA Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.coms offering. "This "CAPLYTA Drug...
July 21, 2023
/PRNewswire/ -- The "RZ358 Emerging Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.coms offering. "This "RZ358...
July 21, 2023
/PRNewswire/ -- The "LYBALVI Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.coms offering. "This "LYBALVI Drug...
July 21, 2023
/PRNewswire/ -- The "ABILIFY MYCITE Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.coms offering. "This "ABILIFY...
July 20, 2023
‒ Late-breaking post-hoc data indicate Vabysmo leads to less fibrosis, which may negatively impact vision, than aflibercept in people with diabetic macular edema (DME) – ‒ Real-world data reinforce that first-line
July 20, 2023
‒ Late-breaking post-hoc data indicate Vabysmo leads to less fibrosis, which may negatively impact vision, than aflibercept in people with diabetic macular edema (DME) –‒ Real-world data reinforce that first-line Vabysmo use improves outcomes and extends treatment intervals rapidly during the first four months for p...
July 20, 2023
An experimental antidepressant developed by Neumora Therapeutics has shown promising results in a phase 2 trial, leading the company to plan its pathway to phase 3 testing.
July 20, 2023
Clinical trial met primary endpoint demonstrating comparable total immunoglobulin (Ig) levels when administering XEMBIFY® (Grifols’ subcutaneous Ig) every...
July 20, 2023
WESTLAKE VILLAGE, Calif., July 20, 2023 -- Genelux Corporation , a late clinical-stage immuno-oncology company, today announced two key management promotions, as well as the addition of two new...